Skip to main content

Table 2 Permutation Analysis of Variance (PERMANOVA) results using Adonis in the R environment to determine factors that significantly (P < 0.05) explained variation in microbiota beta diversity

From: Gut Bifidobacteria enrichment following oral Lactobacillus-supplementation is associated with clinical improvements in children with cystic fibrosis

 

N

R2

P value

Baseline

Dominant genus* (category)

50

0.62

0.0001

Exacerbations, (N)

50

0.01

0.81

Hospitalization (yes/no)

50

0.01

0.70

Calprotectin (μg/g of feces)

46

0.01

0.91

Days prescribed antibiotic coverage (N)

50

0.01

0.73

Treatment (LGG or Placebo)

49

0.03

0.64

12-Month visit

Dominant genus* (category)

27

0.53

0.0001

Exacerbations, (N)

19

0.18

0.003

Hospitalization (yes/no)

19

0.13

0.02

Calprotectin (μg/g of feces)

23

0.09

0.048

Days prescribed antibiotic coverage (N)

19

0.19

0.001

Treatment (LGG or Placebo)

26

0.03

0.71

  1. *Based on a weighted Unifrac distance